NCT04603183 2025-12-12
ABIGAIL
MedSIR
Phase 2 Completed
Clinical Trials
10 trialsNCT03328884 2025-04-23
Phenomenal
MedSIR
Phase 2 Completed
NCT04509596 2025-04-01
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
Dizal Pharmaceuticals
Phase 1 Completed
NCT04483505 2023-12-28
ROGABREAST
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 1 Completed
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT05301010 2023-02-27
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 3 Completed
NCT05301530 2022-03-29
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 1 Completed
NCT02511639 2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3 Completed
NCT02664103 2018-02-01
METRO-ABC
Sanofi
Phase 2 Completed
NCT00532714 2011-12-30
Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC
National Cancer Center, Korea
Phase 2 Completed